Literature DB >> 12397642

Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer.

Barbara Bachtiary1, Andreas Obermair, Bettina Dreier, Peter Birner, Gerhard Breitenecker, Tomas-Hendrik Knocke, Edgar Selzer, Richard Pötter.   

Abstract

To obtain information on the incidence and the clinical significance of infection with various types of the human papillomavirus (HPV) in cancer of the uterine cervix, we retrospectively examined the HPV status of 106 patients who had received radical radiotherapy for cervical cancer stages IB to IIIB. DNA was extracted from formalin-fixed, paraffin-embedded biopsies and PCR was carried out to identify HPV types 16, 18, 31, 35, 33 and 45. To detect additional HPV types, consensus PCR products were cloned and sequenced. A catalyzed signal-amplified colorimetric in situ hybridization was carried out in 84 of 106 specimens as a positive control. Response to therapy, progression-free survival (PFS) and cervical cancer-specific survival (CCSS) were the statistical endpoints. Survival analysis was carried out using univariate and multivariate analysis (Cox regression). Ninety-six patients (90.6%) were HPV-positive and 42/96 (43.7%) were positive for multiple HPV types. Eight patients had persistent disease after radiotherapy. From these 8 patients, 7 were infected with multiple HPV types and only 1 patient had an infection with a single HPV type. After a median follow up period of 50 months, patients with multiple HPV infection had a significantly shorter PFS and CCSS compared to those with single HPV infection (24.8% and 34.9% vs. 64% and 60.8%, Log rank, p < 0.01 and 0.04). In multivariate analysis, the presence of multiple HPV types (RR 1.9), node status (RR 2.3), tumor size (RR 3.2) and histologic type (RR 4.8) were independent prognostic factors of CCSS. Our results demonstrate that the presence of multiple HPV types is associated with poor response and with reduced survival in cervical cancer patients who receive radiotherapy as the primary treatment. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397642     DOI: 10.1002/ijc.10708

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Evaluation of different techniques for identification of human papillomavirus types of low prevalence.

Authors:  Ivan Sabol; Martina Salakova; Jana Smahelova; Michal Pawlita; Markus Schmitt; Nina Milutin Gasperov; Magdalena Grce; Ruth Tachezy
Journal:  J Clin Microbiol       Date:  2008-03-05       Impact factor: 5.948

2.  ¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.

Authors:  Shankar Siva; Siddhartha Deb; Richard J Young; Rodney J Hicks; Jason Callahan; Mathias Bressel; Linda Mileshkin; Danny Rischin; David Bernshaw; Kailash Narayan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-15       Impact factor: 9.236

3.  Undetected human papillomavirus DNA and uterine cervical carcinoma: Association with cancer recurrence.

Authors:  Kae Okuma; Hideomi Yamashita; Terufumi Yokoyama; Keiichi Nakagawa; Kei Kawana
Journal:  Strahlenther Onkol       Date:  2016-01       Impact factor: 3.621

4.  Analytical Evaluation of the Human Papillomavirus HPV DNA Array E1-Based Genotyping Assay.

Authors:  Aleksandra Pesic; Amrei Krings; Carola Schreckenberger; Matthias Hempel; Rosemarie Preyer; Andreas M Kaufmann
Journal:  Intervirology       Date:  2019-09-05       Impact factor: 1.763

5.  Superinfection Exclusion between Two High-Risk Human Papillomavirus Types during a Coinfection.

Authors:  Jennifer Biryukov; Craig Meyers
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

6.  Impact of human papillomavirus genotype on response to treatment and survival in patients receiving radiotherapy for squamous cell carcinoma of the cervix.

Authors:  Jannatul Ferdousi; Yutaka Nagai; Tsuyoshi Asato; Makoto Hirakawa; Morihiko Inamine; Wataru Kudaka; Ken-Ichi Kariya; Yoichi Aoki
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

7.  Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test.

Authors:  Dennis van Hamont; Maaike A P C van Ham; Judith M J E Bakkers; Leon F A G Massuger; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

8.  Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay.

Authors:  Stephanie S Liu; Rebecca C Y Leung; Karen K L Chan; Annie N Y Cheung; Hextan Y S Ngan
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

9.  Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.

Authors:  Ruth Holm; Irene Kraus; Hanne Skomedal; Anita Langerød; Gunnar B Kristensen; Heidi Lyng
Journal:  Open Virol J       Date:  2008-10-24

10.  Human papillomavirus infection in Honduran women with normal cytology.

Authors:  N Tábora; J M J E Bakkers; W G V Quint; L F A G Massuger; J A Matute; W J G Melchers; A Ferrera
Journal:  Cancer Causes Control       Date:  2009-08-15       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.